Avanafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for Erectile Dysfunction
Authors:
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 188 (2) , 668-674
Abstract
We investigated the in vitro inhibitory effects of avanafil, a novel, potent inhibitor of phosphodiesterase-5, on 11 phosphodiesterases. We also studied its potentiation of penile tumescence in dogs. Phosphodiesterase assay was done with the 4 phosphodiesterase-5 inhibitors avanafil, sildenafil, vardenafil and tadalafil using 11 phosphodiesterase isozymes. In anesthetized dogs the pelvic nerve was repeatedly stimulated to evoke tumescence. Intracavernous pressure was measured after avanafil or sildenafil administration. Avanafil specifically inhibited phosphodiesterase-5 activity at a 50% inhibitory concentration of 5.2 nM. Avanafil showed higher selectivity (121-fold) against phosphodiesterase-6 than sildenafil and vardenafil (16 to 21-fold) and showed excellent selectivity (greater than 10,000-fold) against phosphodiesterase-1 compared with sildenafil (375-fold). Avanafil also had higher selectivity against phosphodiesterase-11 than tadalafil (greater than 19,000 vs 25-fold). Avanafil also showed excellent selectivity against all other phosphodiesterases. After intravenous administration in anesthetized dogs the 200% effective dose of avanafil and sildenafil on the penile tumescence was 37.5 and 34.6 μg/kg, respectively. After intraduodenal administration the 200% effective dose of avanafil and sildenafil on tumescence was 151.7 and 79.0 μg/kg at the peak time, respectively. Time to peak response with avanafil and sildenafil was 10 and 30 minutes, respectively, indicating a more rapid onset of avanafil. Avanafil has a favorable phosphodiesterase-5 selectivity profile compared to that of marketed phosphodiesterase-5 inhibitors. Avanafil shows excellent in vitro and in vivo potency, and fast onset of action for penile erection. Cumulative data suggest that avanafil has a promising pharmacological profile for erectile dysfunction.Keywords
This publication has 19 references indexed in Scilit:
- Investigational noncardiovascular uses of phosphodiesterase-5 inhibitorsExpert Opinion on Pharmacotherapy, 2011
- Overview of PDEs and Their RegulationCirculation Research, 2007
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophyNature Medicine, 2005
- Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile DysfunctionCirculation, 2004
- Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humansCellular Signalling, 2003
- Characterization and effects of methyl-2- (4-aminophenyl)-1,2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5)Biochemical Pharmacology, 2000
- Isolation and Characterization of Two Novel Phosphodiesterase PDE11A Variants Showing Unique Structure and Tissue-specific ExpressionJournal of Biological Chemistry, 2000
- Identification of Human PDE7B, a cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 2000
- Striatum‐ and testis‐specific phosphodiesterase PDE10AEuropean Journal of Biochemistry, 1999
- A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertensionLife Sciences, 1996